Add BrightSurf on Google Email

Penn-Developed CAR T Cells Suppress GI Solid Tumor Cells, Without Toxicity to Healthy Tissue, in Preclinical Research

Researchers at Penn Medicine have discovered a new approach to treat solid cancers using CDH17CAR T cells, which selectively target and eliminate gastrointestinal (GI) solid tumors like gastric, pancreatic, and colorectal cancers in preclinical models. Unlike other immunotherapies, CDH17CAR T cells do not show toxicity to healthy tissues.

COVID vaccination is also recommended for people with cancer

A comprehensive review of over 60 studies confirms that COVID vaccination is around 80% effective in protecting people with cancer against SARS-CoV-2 infection. The mRNA vaccines were found to be the most effective, and multiple vaccinations are recommended for better protection.

SourceLeibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute -·JournalNature Reviews Clinical Oncology·TypeLiterature review·DateMar 14, 2022

Penn Medicine awarded $14 million NIH grant to apply CAR T immunotherapies to match more patients in need of kidney transplants

A clinical trial will harness synthetic chimeric antigen receptor (CAR) T cells to deplete immune B cells and plasma cells producing donor-specific antibodies, aiming to achieve a compatible kidney match for patients with pre-existing antibodies. The NIH-funded study, led by Penn Medicine, intends to begin enrolling patients in 2022.

New study reveals how epithelial cells in the body naturally eliminate “precancerous” ones

Researchers have identified a novel immune-like mechanism by which healthy epithelial cells recognize and eliminate precancerous cells through a MHC class I-LILRB3 interaction. This process generates mechanical force to extrude the precancerous cells from the body, offering new hope for cancer prevention and treatment.

SourceWaseda University·JournalNature Immunology·TypeExperimental study·DateDec 15, 2021

Penn study finds solid-tumor cancer patients ineligible for clinical trials receive immunotherapy at greater rates despite lack of benefits

A nationwide study published in JAMA Oncology found that immunotherapy use among trial-ineligible solid-tumor cancer patients increased significantly between 2014 and 2019, yet no survival benefit was observed. Researchers emphasize cautious use of immunotherapies for this population due to potential early harm.

SourceUniversity of Pennsylvania School of Medicine·JournalJAMA Oncology·TypeMeta-analysis·DateNov 9, 2021

Adoptive cell therapy plus checkpoint inhibitors show promise in non-small cell lung cancer

Researchers at H. Lee Moffitt Cancer Center & Research Institute found that combining checkpoint inhibitors with adoptive cell therapy improves treatment outcomes for patients with non-small cell lung cancer. The study showed promising anti-tumor activity, with 11 out of 16 patients experiencing tumor regression.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateAug 12, 2021

How Hypoxia Influences Spatial Gene Expression Variations in Pancreatic Cancer

Researchers discovered that hypoxia induces regional variations in gene-expression patterns in pancreatic cancer, with specific subpopulations of cancer cells surviving under hypoxic conditions. These findings suggest a link between hypoxia and aggressive tumor behavior, highlighting the need for targeted treatments.

SourceCactus Communications·JournalCancer Biology and Medicine·TypeExperimental study·DateAug 11, 2021

High levels of circulating DNA may signal faster progression of lung cancer

Research suggests that high levels of circulating DNA, specifically human telomerase reverse transcriptase (hTERT), can indicate a faster progression of lung cancer and lower overall survival. Patients with lower hTERT levels had improved time to progression and higher overall survival rates compared to those with higher levels.

SourceInternational Association for the Study of Lung Cancer·JournalJournal of Thoracic Oncology·DateFeb 1, 2011

Concentration, timing and interactions are key when it comes to dietary compounds

Agricultural Research Service chemist Thomas Wang found that resveratrol, a bioactive compound in grapes and plant foods, can inhibit cancer cell growth but also increase tumor vessel development with prolonged exposure. The study suggests that diet complexity and gene expression are key layers in cancer development.

A new mechanism regulates type I interferon production in white blood cells

Researchers have discovered a new mechanism that regulates the production of type I interferon, an important protein for clearing viral infections. This mechanism involves a protein-protein interaction between surface receptors on plasmacytoid dendritic cells and class I major histocompatibility complex molecules.

SourceInstitut de recherches cliniques de Montreal·JournalJournal of Experimental Medicine·DateJan 12, 2009